{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-027510","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.701703+00:00","generated_at":"2026-06-05T15:09:43.497547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma reports Q4 2023 GAAP net loss $8.5M; non-GAAP net profit $1.4M; YUPELRI net sales up 9% to $60.6M","bullets":["Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.","GAAP net loss of $8.5M in Q4; achieved non-GAAP net profit of $1.4M, driven by YUPELRI growth and expense management.","Completed $325M capital return program early Jan 2024, reducing shares outstanding by 37%.","YUPELRI hospital volumes grew 46% YoY, exceeding targets; CYPRESS study enrollment on track for H2 2024.","Ampreloxetine granted FDA Orphan Drug Designation; investor event planned for Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-027510","json":"https://secwatch.observer/filing/0001104659-24-027510.json","markdown":"https://secwatch.observer/filing/0001104659-24-027510.md","text":"https://secwatch.observer/filing/0001104659-24-027510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/tm247202d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:09:43.497547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8964cfa13c1554c9029fbb9f157b5126b6208ccc","claim":"Theravance Biopharma, Inc. reported full year ended December 31, 2023 results: revenue $57.2 million.","evidence_excerpt":"· Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$57.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bd8c4d5ab686e1bec8d08461510dd3b1b7740868","claim":"Theravance Biopharma, Inc. reported Q4 2023 results: net income $8.5 million.","evidence_excerpt":"· GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2023"},{"label":"Net income","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}